---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-016162"
form_type: "8-K/A"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:24:36.694000+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports Q1 2024 results; Annamycin shows 62% CRc in 1st/2nd line AML

## Summary
- R&D expense $4.3M, G&A $2.4M; cash $16.8M sufficient into Q4 2024.
- MB-106 interim data: CRc 62% (54% CR) in 1st/2nd line AML (N=13).
- All lines CRc 45% across 20 subjects; median durability 4.9 months and climbing.
- Milestones: complete MB-106 H1 2024; EOP2 meeting H1 2024; pivotal trial H1 2025.
- Received EMA Orphan Drug Designation for Annamycin in AML; U.S. patents issued.

## SEC filing metadata
- accession: 0001437749-24-016162
- form_type: 8-K/A
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774924016162/0001437749-24-016162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774924016162/mbrx20240513_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-016162
- JSON: https://secwatch.observer/filing/0001437749-24-016162.json
- Plain text: https://secwatch.observer/filing/0001437749-24-016162.txt

## Key facts
- Earnings Releases
  Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 13, 2024, Moleculin Biotech, Inc. issued an updated press release announcing its financial results for the quarter ended March 31, 2024 and recent operational highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774924016162/0001437749-24-016162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.